Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aurora Biosciences (ABSC) -- Ignore unavailable to you. Want to Upgrade?

To: silInv who wrote (218)	10/29/1999 3:23:00 PM
From: tuck	Read Replies (1) \| Respond to of 359

silInv, Looks great except for this little caveat: "However, a portion of anticipated fourth quarter revenues may be at risk due to a delay in installation of Module Two components." Maybe that's why we're off a bit today. No matter, I'm in this one for the long haul. Cheers, Tuck

To: silInv who wrote (218)	11/23/1999 10:00:00 AM
From: tuck	Respond to of 359

silInv, Looks like good timing in selling on my part. ABSC has lost Lilly as UHTSS customer: biz.yahoo.com This is somwhat offest by Bristol-Myers becoming a VIPR buyer: biz.yahoo.com But the stock is in the 12s and could go lower. It is odd that Lilly even started as a customer if they thought their internal screening division (Sphinx) was that good. Hedging their bets, I guess. I wonder if they will try to compete with Aurora, or keep it to themselves. Cheers, Tuck